News | March 01, 2023
AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Receives regulatory approval for its molecule ‘Selumetinib’ in India
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
The initiative launched in 2019 has touched over 10,000 lives with 500+ screening camps and aims to double its reach in the next 2 years
Sanjeev is currently the Country President for AstraZeneca Malaysia
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
In the next six months, the program aims to screen 4,000 women from underprivileged communities in and around Mathura
Subscribe To Our Newsletter & Stay Updated
